Business
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44th Annual J.P. Morgan
About this update from Novocure Limited
[{"type":"text","content":"\nPreliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million\n\n\nNovocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14, 2026\n\n\n BAAR, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).\n\n\n“Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exciting growth opportunities we have in 2026,” said Frank Leonard, CEO, Novocure. “We have built the team and capabilities to support multiple product launches in the coming year while ensuring the company is on a clear path to profitability.”\n\n\nFinancial updates for the year and fourth quarter ended December 31, 2025*:\n\n\n\nTotal preliminary net revenues for the year were $655.4 million, an increase of 8% compared to the prior year.\n\n\n\nTotal preliminary net revenues for the fourth quarter were $174.4 million, an increase of 8% compared to the same period in 2024.\n\n\nThe U.S., Germany, France and Japan contributed $101.6 million, $21.6 million, $20.5 million and $10.2 million in net revenue, respectively, with other active markets contributing $15.8 million.\n\n\n\nRevenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.6 million.\n\n\n\nRecognized revenue from Optune Lua® in the quarter was $3.5 million, including $2.4 million from non-small cell lung cancer (NSCLC) and $1.1 million from malignant pleural mesothelioma (MPM).\n\n\n\n\n\n\nCash, cash equivalents and short-term investments were $448.3 million as of December 31, 2025, after repayment of $561 million of convertible notes at maturity in November 2025.\n\n\n\nOperational updates for the year and fourth quarter ended December 31, 2025:\n\n\n\nAs of December 31, 2025, there were 4,620 total active patients on TTFields therapy globally.\n\n\n\nOptune Gio®\n\n\n1,609 Optune Gio prescriptions for the treatment of glioblastoma (GBM) were received in the quarter, an increase of 6% from the same period in 2024. ...